Lieven Meerpoel

This inventor holds 97 USPTO granted patents and 13 published patent applications, plus 31 CIPO patents and 41 EPO patents, primarily in Nucleoside Analogues (CPC class C07D487-04). Top assignees: Janssen Pharmaceutica Nv, Astex Therapeutics Limited, Other. Active years: 1999-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lieven Meerpoel. Retrieved from https://idiyas.com/inventor/lieven-meerpoel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 97 (Patent Applications = 13)

% Patents Active = 79.4

CIPO Patents = 31 (Patent Applications = 13)

EPO Patents = 41 (Patent Applications = 40)

Average Co-Inventor Count = 5.6

ph-index = 15

Forward Citations = 568(Granted Patents)

Forward Citations (Not Self Cited) = 456(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Merksplas, BE (1999)
Beerse, 2340, BE (2002)
Beerse B-2340, BE (2002)
Turnhoutseweg, BE (2015 - 2018)
Beerse, BE (2001 - 2024)

Company Filing History:

85 out of 2,101

Janssen Pharmaceutica Nv

patents

9 out of 126

Astex Therapeutics Limited

patents

3 out of 834,570

Other

patents

Years Active: 1999-2024

Loading Chart...

Areas of Expertise:

Nucleoside Analogues

PRMT5 Inhibitors

PI3K Inhibitors

NIK Inhibitors

Azaindoline Derivatives

Quinoxaline Derivatives

Thiohydantoin Derivatives

Pyridine Derivatives

Kinase Modulators

Heteroaromatic Derivatives

Bicyclic Compounds

Aromatic Rings

97 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12145961 - Spirobicyclic analogues (2024-11-19),

2. 11993614 - Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors (2024-05-28),

3. 11883367 - 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors (2024-01-30),

4. 11702441 - Spirobicyclic analogues (2023-07-18),

5. 11318157 - 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors (2022-05-03),

6. 11267804 - (R)-8-(1-((3-fluorophenyl)amino)ethyl)-N-(2-hydroxyethyl)-2-morpholinoquinoxaline-6-carboxamide for inhibiting phosphoinositide-3-kinase activity (2022-03-08),

7. 11236084 - Substituted azaindoline derivatives as NIK inhibitors (2022-02-01),

8. 11186589 - Cyanoindoline derivatives as NIK inhibitors (2021-11-30),

9. 11180487 - Substituted cyanoindoline derivatives as NIK inhibitors (2021-11-23),

10. 11136311 - Heteroaromatic derivatives as NIK inhibitors (2021-10-05),

11. 11130751 - Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors (2021-09-28),

12. 11098062 - Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors (2021-08-24),

13. 11059850 - Spirobicyclic analogues (2021-07-13),

14. 11001569 - 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors (2021-05-11),

15. 10981926 - Substituted thiohydantoin derivatives as androgen receptor antagonists (2021-04-20),

Title: Lieven Meerpoel: Pioneering Innovations in Pharmaceutical Industry

Introduction

Lieven Meerpoel, a visionary inventor hailing from Beerse, BE, has captivated the industry with his dedication to pushing the boundaries of what is possible through his groundbreaking inventions and patents. With 96 patents to his name, Lieven Meerpoel has solidified his reputation as a trailblazer in the field of pharmaceutical innovation.

Latest Patents

Lieven Meerpoel's latest patents include "Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors" and "6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors." These inventions highlight his relentless pursuit of creating impactful solutions in the realm of PRMT5 inhibitors, showcasing his ingenuity and expertise.

Career Highlights

Throughout his illustrious career, Lieven Meerpoel has left an indelible mark on the industry. Having worked at renowned companies like Janssen Pharmaceutica Nv and Astex Therapeutics Limited, he has demonstrated his ability to innovate and drive meaningful change in the pharmaceutical sector. Lieven Meerpoel's innovative spirit continues to inspire others to strive for excellence and innovation in their respective fields.

Collaborations

Lieven Meerpoel has collaborated with esteemed colleagues such as Olivier Alexis Georges Querolle and Leo Jacobus Jozef Backx, further underscoring his commitment to fostering collaborative partnerships within the industry. Through these collaborations, Lieven Meerpoel has been able to leverage diverse perspectives and expertise to enhance the impact of his inventions and patents.

Conclusion

In conclusion, Lieven Meerpoel's unwavering dedication to innovation and his pioneering inventions in the pharmaceutical industry have positioned him as a visionary inventor. His relentless pursuit of excellence and his commitment to pushing the boundaries of what is possible serve as a testament to his enduring impact on the field of pharmaceutical innovation. Lieven Meerpoel's legacy as a trailblazer continues to inspire future generations to aspire to greatness in the world of inventions and patents.

Profile summary based on public USPTO records.